Five of these compounds representing 3 different chemotypes selectively inhibited growth of BRCA1-, BRCA2-deficient human cancer cells and BRCA1-deficient (with low expression level) primary cells from leukemia patients. This evidence concerns the gene BRCA1 and leukemia.